Pouchitis
1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Novo NordiskBAGSVAERD DENMARK, Denmark
1 programLiraglutide Pen InjectorPHASE_2Peptide1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
Prevail TherapeuticsMirikizumab - Intravenous
Novo NordiskLiraglutide Pen Injector
EppendorfTryptophan 25mg/kg bodyweight
Clinical Trials (3)
Total enrollment: 53 patients across 3 trials
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
Start: Aug 2025Est. completion: Apr 202725 patients
Phase 4Recruiting
Efficacy of Liraglutide Therapy in Patients With IPAA
Start: Mar 2022Est. completion: Oct 20238 patients
Phase 2Terminated
Exploring the Influence of Trptophan on the Treatment of Pouchitis
Start: Apr 2025Est. completion: Apr 202720 patients
N/ANot Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 53 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.